Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 GBX | -1.04% |
|
+7.95% | -34.48% |
23/05 | Windward wins deal; Kodal progresses at Bougouni | AN |
23/05 | Roquefort Therapeutics plc Announces Executive and Board Changes | CI |
Business Summary
Number of employees: 10
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Europe and Australia
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 16/22/16 |
Chairman | 51 | 17/20/17 | |
Martin Evans
BRD | Director/Board Member | 83 | 16/22/16 |
Graham Robertson
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 05/22/05 |
Darrin Disley
BRD | Director/Board Member | 57 | 16/22/16 |
Chairman | 51 | 17/20/17 | |
Martin Evans
BRD | Director/Board Member | 83 | 16/22/16 |
Ajan Reginald
CEO | Chief Executive Officer | 52 | 16/22/16 |
Simon Sinclair
BRD | Director/Board Member | 52 | 20/22/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 129,149,998 | 51,144,652 ( 39.60 %) | 0 | 39.60 % |
Company contact information
Roquefort Therapeutics Plc
Eccleston Yards 25 Eccleston Place
SW1W 9NF, London
+44 20 3918 8633
http://www.roquefortplc.com![address Roquefort Therapeutics plc(ROQ)](https://cdn.zonebourse.com/static/address/120527678.png)
Sector
1st Jan change | Capi. | |
---|---|---|
-34.48% | 78.39L | |
-3.21% | 12TCr | |
+26.62% | 6.71TCr | |
+6.38% | 6.45TCr | |
+14.41% | 4.45TCr | |
+12.77% | 4.27TCr | |
+26.64% | 3.66TCr | |
+6.84% | 2.58TCr | |
-5.19% | 2.2TCr | |
-0.25% | 1.86TCr |
- Stock Market
- Equities
- ROQ Stock
- Company Roquefort Therapeutics plc